Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

78.66 USD +0.21 (+0.27%)
Official Closing Price Updated: 7:58 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,691,587
Open 79.17
Bid (Size) 77.79 (1)
Ask (Size) 78.72 (1)
Prev. Close 78.45
Today's Range 77.77 - 79.64
52wk Range 62.48 - 110.36
Shares Outstanding 211,969,163
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC) 
From Business Wire News Releases
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease 
From Business Wire News Releases

Performance

YTD
-9.01%
-9.01%
1 Month
-15.42%
-15.42%
3 Month
-5.51%
-5.51%
6 Month
-16.23%
-16.23%
1 Year
+3.72%
+3.72%

More News

Read More
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
From Business Wire News Releases
Incyte to Present at Upcoming Investor Conference
From Business Wire News Releases
Nasdaq 100 Movers: VRSK, INCY
Tags Stocks
From Market News Video
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
From Business Wire News Releases
FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease
Tags Biotech News atopic dermatitis
From Benzinga
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Fact
From Business Wire News Releases
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Business Wire News Releases
Sum Up The Pieces: XLV Could Be Worth $128
Tags ETFs
From ETF Channel
Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]